金融界3月7日消息，据CDE官网沟通交流公示，于3月7日收到吉林天衡英睿制药有限公司申请的“III类会议”，当前状态“处理中”。
根据《药物研发与技术审评沟通交流管理办法》（2020年第48号通告），沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议，就关键阶段重大问题进行沟通交流，Ⅲ类会议一般安排在申请后75日内召开。
吉林天衡英睿制药有限公司，成立于2020年，位于通化市，是一家以从事医药制造业为主的企业。企业注册资本3080万人民币。
通过天眼查大数据分析，吉林天衡英睿制药有限公司参与招投标项目8次，专利信息1条，此外企业还拥有行政许可7个。
主要股东信息显示，吉林天衡英睿制药有限公司由吉林天衡药业有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.